RU2642623C2 - Способ прогнозирования риска развития злокачественного новообразования или диагностики злокачественного новообразования у особи женского пола - Google Patents

Способ прогнозирования риска развития злокачественного новообразования или диагностики злокачественного новообразования у особи женского пола Download PDF

Info

Publication number
RU2642623C2
RU2642623C2 RU2014140432A RU2014140432A RU2642623C2 RU 2642623 C2 RU2642623 C2 RU 2642623C2 RU 2014140432 A RU2014140432 A RU 2014140432A RU 2014140432 A RU2014140432 A RU 2014140432A RU 2642623 C2 RU2642623 C2 RU 2642623C2
Authority
RU
Russia
Prior art keywords
neurotensin
pro
female
breast cancer
risk
Prior art date
Application number
RU2014140432A
Other languages
English (en)
Russian (ru)
Other versions
RU2014140432A (ru
Inventor
Андреас БЕРГМАНН
Олле МЕЛАНДЕР
Original Assignee
Сфинготек Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сфинготек Гмбх filed Critical Сфинготек Гмбх
Publication of RU2014140432A publication Critical patent/RU2014140432A/ru
Application granted granted Critical
Publication of RU2642623C2 publication Critical patent/RU2642623C2/ru

Links

Images

Classifications

    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
RU2014140432A 2012-03-08 2013-03-08 Способ прогнозирования риска развития злокачественного новообразования или диагностики злокачественного новообразования у особи женского пола RU2642623C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261608346P 2012-03-08 2012-03-08
EP12158679 2012-03-08
US61/608,346 2012-03-08
EP12158679.6 2012-03-08
EP12165054.3 2012-04-20
EP12165054 2012-04-20
PCT/EP2013/054800 WO2013132089A2 (en) 2012-03-08 2013-03-08 A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Publications (2)

Publication Number Publication Date
RU2014140432A RU2014140432A (ru) 2016-04-27
RU2642623C2 true RU2642623C2 (ru) 2018-01-25

Family

ID=49117445

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014140432A RU2642623C2 (ru) 2012-03-08 2013-03-08 Способ прогнозирования риска развития злокачественного новообразования или диагностики злокачественного новообразования у особи женского пола

Country Status (7)

Country Link
US (2) US20150031144A1 (enExample)
EP (1) EP2823313B1 (enExample)
JP (1) JP6290795B2 (enExample)
CN (1) CN103308689B (enExample)
IN (1) IN2014MN01936A (enExample)
RU (1) RU2642623C2 (enExample)
WO (1) WO2013132089A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101596A2 (en) 2013-12-30 2015-07-09 Oncoprevent Gmbh Neurokinin-1 receptor antagonists for use in a method of prevention of cancer
CN104237535B (zh) * 2014-09-30 2016-02-10 天津市泌尿外科研究所 神经降压素在诊断去势抵抗性前列腺癌神经内分泌化亚型和判断预后中的应用
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
RU2745751C2 (ru) * 2015-02-27 2021-03-31 Сфинготек Гмбх Способ прогнозирования риска развития ожирения у субъекта
KR102618553B1 (ko) * 2022-08-31 2023-12-27 숙명여자대학교산학협력단 당뇨병 환자의 유방암 발병 예측 및 유방암 환자의 예후 예측용 바이오마커

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093373A2 (en) * 2006-02-14 2007-08-23 Università Degli Studi Di Siena Branched multimeric peptides for tumor diagnosis and therapy
US20080280306A1 (en) * 2005-01-26 2008-11-13 Sphingotec Gmbh Immunoassay For Determining The Release Of Neurotensin Into The Circulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2003020746A1 (en) 2001-08-30 2003-03-13 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20050233393A1 (en) * 2004-02-27 2005-10-20 Wynne-Edwards Katherine E Dynamic hormone index as a biomarker for disease
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
EP1793847A2 (en) 2004-09-21 2007-06-13 NascaCell IP GmbH Use of microproteins as tryptase inhibitors
US8449864B2 (en) * 2006-10-20 2013-05-28 The Board Of Trustees Of The Leland Stanford Junior University Neurotensin as a marker and therapeutic target for sepsis
WO2009044561A1 (ja) * 2007-10-03 2009-04-09 Shizuoka Prefecture 抗ｐｒｏＮＴ／ＮＭＮモノクローナル抗体
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
EP2374003B1 (en) * 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
WO2011073214A2 (en) 2009-12-14 2011-06-23 Scil Proteins Gmbh A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
CN103308670B (zh) * 2012-03-08 2017-06-09 思芬构技术有限公司 用于预测对象患糖尿病和/或代谢综合征的风险的方法
CA2886814C (en) * 2012-10-02 2021-09-07 Sphingotec Gmbh A method for predicting the risk of getting cancer or diagnosing cancer in a female subject

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280306A1 (en) * 2005-01-26 2008-11-13 Sphingotec Gmbh Immunoassay For Determining The Release Of Neurotensin Into The Circulation
WO2007093373A2 (en) * 2006-02-14 2007-08-23 Università Degli Studi Di Siena Branched multimeric peptides for tumor diagnosis and therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARRAWAY R.E. ET AL., "Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools"// PEPTIDES, vol. 27, no. 10, pages 2445- 460, , формула, описание параграф [2.1.], [2.2.1.], [3.1.], [3.2.], [3.3.], [3.5.], [006.]. *
CARRAWAY R.E. ET AL., "Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools"// PEPTIDES, vol. 27, no. 10, pages 2445- 460, реферат, формула, описание параграф [2.1.], [2.2.1.], [3.1.], [3.2.], [3.3.], [3.5.], [006.]. ERNST A. ET AL., "Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation"// PEPTIDES, vol. 27, no. 7, pages 1787-1793, реферат, формула, описание стр. 1788, 1791-1792. KITABGI P. ET AL., "Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases"// PEPTIDES, vol. 27, no. 10, pages 2508-2514, реферат, формула, описание стр. 2511-2513. *
ERNST A. ET AL., "Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation"// PEPTIDES, vol. 27, no. 7, pages 1787-1793, , формула, описание стр. 1788, 1791-1792. *
KITABGI P. ET AL., "Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases"// PEPTIDES, vol. 27, no. 10, pages 2508-2514, , формула, описание стр. 2511-2513. *

Also Published As

Publication number Publication date
EP2823313B1 (en) 2019-09-18
WO2013132089A2 (en) 2013-09-12
CN103308689A (zh) 2013-09-18
JP2015512047A (ja) 2015-04-23
CN103308689B (zh) 2017-04-12
US20210109102A1 (en) 2021-04-15
IN2014MN01936A (enExample) 2015-07-10
EP2823313A2 (en) 2015-01-14
JP6290795B2 (ja) 2018-03-07
WO2013132089A3 (en) 2014-02-20
US20150031144A1 (en) 2015-01-29
WO2013132089A4 (en) 2014-04-10
RU2014140432A (ru) 2016-04-27

Similar Documents

Publication Publication Date Title
US20210109102A1 (en) Method for predicting the risk of getting cancer or diagnosing cancer in a female subject
RU2652304C2 (ru) Способ прогнозирования риска развития сердечно-сосудистой патологии у особи женского пола
US20200326350A1 (en) Method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
ES2879023T3 (es) Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular
CA2886814C (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
ES2752038T3 (es) Método para predecir el riesgo de contraer cáncer de mama en mujeres
HK1189658A (en) A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome
HK1189658B (en) A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome
HK1189656A (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
HK1189659B (en) A method for predicting the risk of getting a cardiovascular event in a female subject
HK1189656B (en) A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
HK1189659A (en) A method for predicting the risk of getting a cardiovascular event in a female subject
HK1215302B (en) Fasting levels of growth hormone as a predictive marker of cardiovascular risk